Listing 3 - Actual negotiations

Indication:

Ulcerative Colitis

Indication:

Neoadjuvant-adjuvant treatment of adult patients with stage III or stage IV melanoma

Indication:

Gastric or gastroesophageal junction (GEJ) adenocarcinoma in adult patients, locally advanced unresectable or metastatic, HER2-positive, first-line treatment in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by a validated test

Indication:

Biliary tract carcinoma (BTC) in adult patients, locally advanced unresectable or metastatic, in combination with chemotherapy

Indication:

Primary hypercholesterolemia (non-familial and heterozygous familial) with atherosclerotic cardiovascular disease

Indication:

Hepatocellular carcinoma (HCC)

Indication:

Unresectable or metastatic melanoma in adult and pediatric patients 12 years of age or older who have not received prior systemic therapy for unresectable or metastatic melanoma

Indication:

Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab)

Indication:

Metastatic colorectal cancer in adult patients who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents. ( in combination with bevacizumab)

Indication:

Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy, in adult patients